Medical experts have decried the skyrocketing cost and unavailability of diabetes medications in the country. This was even ...

medication regimens and sensor devices. Despite its leadership in pharmaceutical products for diabetes, Sanofi is not a market leader in blood glucose meters and devices, with firms such as Abbott ...

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Sanofi India net profit down 46% in quarter ended September 30: Our Bureau, New Delhi Friday, November 8, 2024, 11:35 Hrs [IST] Sanofi India has registered 46 per cent decline in ...

Sales of the drug in the United States rose 19.1% ... Tzield, approved to delay the onset of type I diabetes, was added to Sanofi’s portfolio with the 2023 acquisition of Provention Bio.

With the rising popularity of telehealth providers offering GLP-1 medications like Ozempic, the terminology can get confusing ...

Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare disease targets.

The company is banking on revenue from its Sanofi deal and vaccines in development ... Syamnath Future of Healthcategory Eli ...

Among Sanofi’s rare disease drugs, new rare blood disorder drug Altuviiio, a once-weekly new class of factor VIII therapy for hemophilia A, recorded sales of €172 million in the third quarter ...